USFDA study shows Evusheld retains neutralising activity against Omicron: AstraZeneca

in #health • 4 years ago

image.png

Evusheld is the first long-acting antibody to receive emergency use authorisation in the US for pre-exposure prophylaxis of COVID-19, in addition to authorisations in other countries, and the drug firm is now working with regulators on applications for the use of Evusheld in treating COVID-19, he added. The Omicron variant was not in circulation during the Evusheld clinical trials

#covid #vaccine #astrazeneca
4 years ago in #health by
$0.00
    Reply 0

    Coin Marketplace

    STEEM 0.05
    TRX 0.29
    JST 0.045
    BTC 66375.55
    ETH 1915.93
    USDT 1.00
    SBD 0.38